Feature | May 19, 2014

Pacemaker, Defibrillator Patients Adhering to Remote Monitoring Saw More Than Double Survival Rate

Data presented during at Heart Rhythm 2014 is industry’s largest study of remote management of pacemaker patients

May 19, 2014 — St. Jude Medical announced that data presented during a late-breaking clinical trial session at the 2014 annual scientific sessions of the Heart Rhythm Society (HRS) found an association between adherence to remote monitoring with the Merlin remote monitoring system and a reduction in patient mortality. Results from more than 260,000 patients implanted with either pacemakers or defibrillators demonstrated that patients with high adherence to remote monitoring had more than twice (2.4x) the probability of survival than that of patients without remote monitoring.

The prospective, observational study of U.S. patients also found that the greater the adherence to remote monitoring, the better the patient fared. Patients with high adherence to remote monitoring — measured as weekly transmission of patient data from the [email protected] System to the Merlin.net patient care network at least 75 percent of the time — overall had a 58 percent reduced likelihood of mortality than patients not using remote monitoring and a 35 percent reduced likelihood of mortality than patients with low remote monitoring. Though there was geographic variability, socioeconomic factors were not associated with remote monitoring use.

“This study is the first of its kind to find increased survival when remote monitoring is utilized in pacemaker patients,” said Suneet Mittal, M.D., director of EP at the Valley Hospital Health System of N.Y. and N.J. “Furthermore, our data suggest that, irrespective of whether a patient has a pacemaker or defibrillator, higher use of remote monitoring is associated with better survival. Although these associations require further investigation, these important observations should have significant implications for individual patient care and best-practice guidelines.”

All St. Jude Medical U.S. Food and Drug Administration (FDA) approved implantable cardiac devices capable of radiofrequency (RF) remote monitoring were included in the study, which had a cohort of 262,564. This is the largest study to date of remote monitoring pacemaker patients, and one of the largest for remote monitoring overall.

“Patients with implanted cardiac devices are typically required to visit doctors’ offices several times per year to have their device performance checked, which for many can be impractical. This new research demonstrates that the Merlin patient care system not only adds convenience for physicians and patients, it helps patients to live longer,” said Mark D. Carlson, M.D., chief medical officer for St. Jude Medical.

For more information: www.sjm.com

Related Content

common adult CT examinations, computed tomography, diagnostic reference levels, DRLs, radiation dose, achievable dose, AD
News | Radiation Dose Management| February 23, 2017
Using data from the world’s largest computed tomography (CT) dose index registry, researchers have established national...
News | Cardiac Diagnostics| February 17, 2017
Levels of a protein in the blood associated with heart disease are also linked to early-stage brain damage, according...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Arterial Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
Biotronik, ProMRI Configurator tool, MR-conditional cardiac devices, ProMRI SystemCheck
Technology | Implantable Cardiac Monitor (ICM)| February 14, 2017
Biotronik has developed an online tool that streamlines the workflow for physicians selecting the right magnetic...
News | Hypertension| February 13, 2017
Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s...
Xarelto, rivaroxaban, COMPASS study, ends early,
News | Antiplatelet and Anticoagulation Therapies| February 09, 2017
February 9, 2017 — Janssen Research & Development LLC (Janssen) announced that the Phase 3 COMPASS trial is stopp
Medtronic, IDE approval, IN.PACT Admiral drug-coated balloon, DCB, end-stage renal disease
News | Drug-Eluting Balloons| February 08, 2017
Medtronic plc announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration...
CSI, LIBERTY 360 Study, ISET 2017, six-month data, lower extremity PAD
News | Atherectomy Devices| February 08, 2017
February 8, 2017 — Cardiovascular Systems (CSI) presented six-month data from its LIBERTY 360° post-market study in a
Penn Medicine, heart failure causes, YAP and TAZ proteins, Journal of Clinical Investigation study
News | Heart Failure| February 07, 2017
February 7, 2017 — Of the more than 700,000 Americans who suffer a heart attack each year, about a quarter go on to d
Overlay Init